Jordan Chose EVO ICL Because It Was the Best Choice For His Health
Before the EVO ICL procedure, my relationship with my vision was one of constant struggle. I had been in contacts and glasses most of my life, and it was always just a hassle. My vision was just terrible.
Before the EVO ICL procedure, my relationship with my vision was one of constant struggle. I had been in contacts and glasses most of my life, and it was always just a hassle. My vision was just terrible.
EVO ICL: Phenomenal
I chose the EVO ICL over other options because it was the best overall choice for my eye health.
My biggest concern with considering vision correction and the EVO ICL procedure was the possibility of "what if it doesn't work?" or "what if it's really painful?" The EVO ICL allows you to retain the natural shape of your cornea. So, worst case, we just remove it. It became a no-brainer, easy solution.
If I had to choose one word to describe the EVO ICL procedure, it would be: phenomenal.
The versatility and just the incredible technology behind it and the crystal-clear vision that I've been able to experience following the procedure, it has been a world of difference in a million ways, day-to-day. It has been absolutely worth it.
Jordan Rogers has ICL lenses and is sponsored by STAAR Surgical.
Important Safety Information for EVO/EVO+ ICL
The EVO/EVO+ ICL is designed for the correction/reduction of up to -20 diopters (D) of nearsightedness with up to 6 D of astigmatism for patients who are 21 to 60 years of age and for patients 21 years of age or older who have been treated with an intraocular lens. Implantation of the EVO/EVO+ ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse events: additional surgeries, cataract formation, transient or persistent loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, corneal swelling, conjunctival irritation, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO/EVO+ ICL dislocation, macular edema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO/EVO+ ICL surgery you should have a complete eye examination and talk with your eye care professional about the EVO/EVO+ ICL procedure, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.
Locale Switcher
Latin America
References
1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
2. MartĆnez-Plaza E, LĆ³pez-Miguel A, LĆ³pez-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
3. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clin Ophthalmol. 2022;16:1541-53.
4. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
5. Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2321-2328.
6. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. Eur J of Ophthalmol. 2007; 17(1): pp. 1-6.
7. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg., Volume 26 , Issue 9 , 1326 - 1331.
8. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.